

LPL Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP14170c

Specification

LPL Antibody (Center) - Product Information

Application	WB, IHC-P, FC,E
Primary Accession	P06858
Other Accession	Q06000 , P49923 , P11152 , P11151 , NP_000228.1 , Q29524
Reactivity	Human
Predicted	Bovine, Mouse, Pig, Rat, Sheep
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Antigen Region	300-327

LPL Antibody (Center) - Additional Information

Gene ID 4023

Other Names

Lipoprotein lipase, LPL, LPL, LIPD

Target/Specificity

This LPL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 300-327 amino acids from the Central region of human LPL.

Dilution

WB~~1:1000-1:2000

IHC-P~~1:10~50

FC~~1:25

E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

LPL Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

LPL Antibody (Center) - Protein Information

Name LPL**Synonyms** LIPD

Function Key enzyme in triglyceride metabolism. Catalyzes the hydrolysis of triglycerides from circulating chylomicrons and very low density lipoproteins (VLDL), and thereby plays an important role in lipid clearance from the blood stream, lipid utilization and storage (PubMed:[11342582](#), PubMed:[27578112](#), PubMed:[8675619](#)). Although it has both phospholipase and triglyceride lipase activities it is primarily a triglyceride lipase with low but detectable phospholipase activity (PubMed:[12032167](#), PubMed:[7592706](#)). Mediates margination of triglyceride-rich lipoprotein particles in capillaries (PubMed:[24726386](#)). Recruited to its site of action on the luminal surface of vascular endothelium by binding to GPIHBP1 and cell surface heparan sulfate proteoglycans (PubMed:[11342582](#), PubMed:[27811232](#)).

Cellular Location

Cell membrane {ECO:0000250|UniProtKB:P11151}; Peripheral membrane protein {ECO:0000250|UniProtKB:P11151}; Extracellular side {ECO:0000250|UniProtKB:P11151}. Secreted. Secreted, extracellular space, extracellular matrix. Note=Newly synthesized LPL binds to cell surface heparan proteoglycans and is then released by heparanase Subsequently, it becomes attached to heparan proteoglycan on endothelial cells (PubMed:27811232). Locates to the plasma membrane of microvilli of hepatocytes with triglyceride-rich lipoproteins (TRL) Some of the bound LPL is then internalized and located inside non- coated endocytic vesicles (By similarity) {ECO:0000250|UniProtKB:P11151, ECO:0000269|PubMed:27811232}


Tissue Location


Detected in blood plasma (PubMed:11893776, PubMed:12641539, PubMed:2340307). Detected in milk (at protein level) (PubMed:2340307).

LPL Antibody (Center) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


LPL Antibody (Center) - Images




LPL Antibody (Center) (Cat. #AP14170c) western blot analysis in HL-60 cell line lysates (35ug/lane). This demonstrates the LPL antibody detected the LPL protein (arrow).



All lanes : Anti-LPL Antibody (Center) at 1:1000-1:2000 dilution Lane 1: MCF-7 whole cell lysate
Lane 2: HL-60 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 53 kDa
Blocking/Dilution buffer: 5% NFDM/TBST.



LPL Antibody (Center) (AP14170c) immunohistochemistry analysis in formalin fixed and paraffin embedded human brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of LPL Antibody (Center) for immunohistochemistry. Clinical relevance has not been evaluated.



Overlay histogram showing Hela cells stained with AP14170c (green line). The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min. The cells were then incubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (AP14170c, 1:25 dilution) for 60 min at 37°C. The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed (OH191631) at 1/400 dilution for 40 min at 37°C. Isotype control antibody (blue line) was Rabbit IgG (1 µg/1x10⁶ cells) used under the same conditions. Acquisition of >10,000 events was performed.

LPL Antibody (Center) - Background

LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism. [provided by RefSeq].

LPL Antibody (Center) - References

Hu, M., et al. Pharmacogenet. Genomics 20(10):634-637(2010)
Romero, R., et al. Am. J. Obstet. Gynecol. 203 (4), 361 (2010) :
Johansen, C.T., et al. Nat. Genet. 42(8):684-687(2010)
Zabaneh, D., et al. PLoS ONE 5 (8) (2010) :
Jugessur, A., et al. PLoS ONE 5 (7), E11493 (2010) :